drugset / Trial / NCT00852787
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
Phase 4
Unknown
30 enrolled
National Institute on Aging (NIA)
University of Toledo Health Science Campus · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.
Timeline
- Start
- 2009-04
- Primary completion
- 2012-05
- Completion
- 2012-05
Publications
- Background Bagrov AY, Shapiro JI. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol. 2008 Jul;4(7):378-92. doi: 10.1038/ncpneph0848. Epub 2008 Jun 10.
- Background Mohmand B, Malhotra DK, Shapiro JI. Uremic cardiomyopathy: role of circulating digitalis like substances. Front Biosci. 2005 Sep 1;10:2036-44. doi: 10.2741/1679.
- Background Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA, Tapilskaya NI, Bzhelyansky A, Reznik VA, Frolova EV, Nikitina ER, Budny GV, Longo DL, Lakatta EG, Bagrov AY. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens. 2008 Dec;26(12):2414-25. doi: 10.1097/HJH.0b013e328312c86a.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digibind | Protein / enzyme biologic | 0.1 mg/kg | Intravenous |
| Subject | Digibind | Protein / enzyme biologic | 0.4 mg/kg | Intravenous |
| Subject | Digibind | Protein / enzyme biologic | 1.6 mg/kg | Intravenous |